## HUM: Humana Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.03 indicates fundamental undervaluation. Consistent execution (3/4 quarters beat estimates). Caution: declining volume (38% of avg), momentum weakening (-2.7% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($242.19)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 6
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. Ex-Dividend Reminder: Pennymac Mortgage Investment Trust, TowneBank and Humana**
- Source: Nasdaq | 20251224T150923 | Somewhat-Bearish | Relevance: 93%
- Pennymac Mortgage Investment Trust (PMT), TowneBank (TOWN), and Humana Inc. (HUM) are set to trade ex-dividend on December 26, 2025, for their upcoming quarterly dividends. Investors should expect a proportional drop in their stock prices reflecting the dividend payouts. The article provides historical dividend charts and estimated annualized yields for each company.

**2. ZeOmega Recognized in 2025 Gartner(R) Market Guide for U.S. Healthcare Payer Care Management Workflow Applications**
- Source: Shreveport Times | 20251227T070847 | Somewhat-Bullish | Relevance: 63%
- ZeOmega has been recognized as a "Visionary Incumbent" in the 2025 Gartner Market Guide for U.S. Healthcare Payer Care Management Workflow Applications, a recognition they believe highlights their efforts to modernize payer care management amid evolving regulatory and technological demands. The company's Jiva Population Health Enterprise Management Platform addresses critical needs in healthcare by leveraging AI and analytics to automate workflows, identify at-risk populations, facilitate data exchange, and enhance member engagement. This acknowledgment affirms ZeOmega's commitment to providing advanced solutions that help health plans adapt to shifting policies, clinical standards, and member expectations, ultimately driving better outcomes.

**3. Azarias Capital Management L.P. Sells 61,443 Shares of Healthcare Services Group, Inc. $HCSG**
- Source: MarketBeat | 20251226T081007 | Neutral | Relevance: 62%
- Azarias Capital Management L.P. has reduced its stake in Healthcare Services Group, Inc. (HCSG) by 19.5%, selling 61,443 shares and now owning 253,363 shares valued at approximately $4.26 million. This makes HCSG the 23rd largest holding in Azarias Capital's portfolio, representing about 1.7% of its total investments. Healthcare Services Group recently beat Q3 earnings estimates with $0.23 EPS and $464.3M in revenue, while institutional ownership stands at nearly 98%, and the stock trades near its 52-week high.

**4. UnitedHealth Group (UNH) Stock: What to Know Before the U.S. Market Opens on Dec. 26, 2025**
- Source: ts2.tech | 20251226T010833 | Neutral | Relevance: 58%
- UnitedHealth Group (UNH) is facing significant operational overhauls, federal scrutiny, and policy risks as the U.S. market reopens after Christmas. Investors are weighing the impact of internal audit-driven changes, ongoing Department of Justice inquiries regarding Medicare billing, and the broader political landscape affecting health insurers. The article details these complex factors and analyst perspectives, highlighting that its upcoming January 27 earnings report will be a key catalyst.

**5. Corient Private Wealth LLC Sells 107,763 Shares of Healthcare Services Group, Inc. $HCSG**
- Source: MarketBeat | 20251224T090948 | Neutral | Relevance: 58%
- Corient Private Wealth LLC significantly reduced its stake in Healthcare Services Group, Inc., selling nearly 50% of its holdings. Despite this, other hedge funds have adjusted their positions with some increasing their stakes in the company. Healthcare Services Group recently surpassed quarterly earnings and revenue estimates, and analysts maintain a "Hold" consensus rating for the stock.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-18 | Morgan Stanley | $262 | $277 | -5% |
| 2025-12-05 | Jefferies | $313 | $253 | +24% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-18 | Morgan Stanley | main | Equal-Weight |
| 2025-12-05 | Jefferies | up | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 8 ($0.14M) |
| Sells | 6 ($1.54M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 57.3% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- Vanguard Group Inc: 11.8% (-0.3%)
- Dodge & Cox Inc.: 9.4% (-0.1%)
- JPMORGAN CHASE & CO: 8.4% (+237.0%)
- Blackrock Inc.: 8.3% (-3.0%)
- State Street Corpora: 4.5% (-0.2%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.03 suggests fair value with growth premium. Balance sheet: strong liquidity (2.0x). Insider selling cluster ($1.5M in 90 days), potential headwind. Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $31.1B |
| Beta | 0.47 |
| 52W Range | $206.87 - $315.35 |
| Short Interest | 4.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.03 |
| Forward P/E | 20.8 |
| Current P/E | 15.2 |
| YoY Growth | -27.0% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 2.4% to -0.3% (-2.7% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 4.3pp (needs >4.0% for momentum thesis). Below SMA200 (1.00x), long-term trend not supportive. RSI neutral at 52. Volume at 38% of 20MA suggests lack of conviction. OFD pattern: +DLL (Support).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -0.28% (CS: 50) | Neutral |
| RSI_14 | 52.0 | Neutral |
| MACD Histogram | 0.25 | Bullish |
| vs SMA20 | 1.007x | Above |
| vs SMA50 | 0.998x | Below |
| vs SMA200 | 1.000x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $258.83
- **Stop Loss:** $242.19 (6.4% risk)
- **Target:** $292.11 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 79
- **Position Value:** $20,447.57
- **Portfolio %:** 20.45%
- **Risk Dollars:** $1,320.00
- **Risk Per Trade:** 1.32%
- **Modifiers:** L1 110% | L2 120% | Combined 1.32x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.10x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with selective risk appetite amid holiday trading. VIX at extreme lows (13.6) signals complacency while positive yield curve (+59bps) and stable economic data support continuation. Focus on quality names with AI/infrastructure exposure while monitoring January volatility reset.*

### Earnings

**Next:** 2026-02-11 (Est: $-3.89)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.83 | $3.24 | +14.6% |
| 2025Q2 | $5.87 | $6.27 | +6.9% |
| 2025Q1 | $10.07 | $11.58 | +15.0% |
| 2024Q4 | $-2.12 | $-2.16 | -1.9% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_20*